Publisher: Biotech Finances


In the Media

Leadiant Biosciences Is Conducting the Registry Study of Revcovi® Treatment in Patients With ADA-SCID

In the Media Icon

Leadiant Biosciences, Inc. announced it is conducting the Registry Study of Revcovi®(elapegademase-lvlr) injection 1.6 mg/ml Treatment in Patients with Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID). The registry study will follow pediatric and adult ADA-SCID patients for two years or longer to collect supplemental information on those being treated with Revcovi… “The information obtained through this… Read More